all CAPS: A Story of Ice and Fire - Part 2

ByAdam J. Brown, MD

Things get a little nerdy in this episode, which focuses on the basic science of what makes the inflammasome tick in CAPS, as well as data on the use of interleukin 1 inhibition. Hint: Listen to “The Inflammasome for Dunces” episode first, and this one will make more sense.

Intro :20
Recap of Part 1 :33
Overview of this episode 1:56
Familial cold autoinflammatory syndrome 3:04
Muckle-Wells syndrome 6:34
The two checkpoint problem 8:36
What do we know about the inhibition of the inflammasome? 11:13
Back to the trebuchet analogy 11:48
Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.

A paper on CARD8 in the setting of CAPS 13:50
Let’s talk about prostaglandins 15:27
There are over 100 mutations in CAPS 18:15
Let’s talk about treatment 18:42
One caveat 25:41
That’s CAPS 26:45
Reach out to me via email and on Twitter 27:03
Episode recap 27:41

We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum

Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com.

Disclosure: Brown reports no relevant financial disclosures.

References:

Agostini L, et al. Immunity. 2004;20:319-325.

Brogan PA, et al. Arthritis Rheum. 2019;71:1955-1963.

Marsaud C, et al. J Rheumatol. 2014;41:1721-1722.

Hawkins PN, et al. NEJM. 2003;348:2583-2584.

Hoffman HM, et al. Lancet. 2004;364:1779-1785.

Hoffman HM, et al. Clin Ther. 2012;34:2091-2103.

Ito S, et al. Arthritis Res Ther. 2014;16:doi:10.1186/ar4483.

Kuemmerle-Deschner JB, et al. Ann Rheum Dis. 2011;70:2095-2102.

Lachmann HJ, et al. NEJM. 2009;360:2416-2425.

Mamoudjy N, et al. Orphanet J Rare Dis. 2017;12:doi:10.1186/s13023-017-0589-1.